Biosimilar adalimumab is making its way to patients, some of whom have expressed concerns about the presence of citrate in some of the available biosimilars.
Biosimilar adalimumab recently entered the European marketplace, and swift adoption by health systems eager to benefit from cost savings means that biosimilar versions are making their way to patients, some of whom have expressed concerns about the presence of citrate in some of the available biosimilars. In the United Kingdom, the National Health Service (NHS) Specialist Pharmacy Service has issued an update on biosimilar adalimumab with a focus on injection site reactions (ISRs) that may be related to the citrate buffer used in some formulations of adalimumab.
The early formulation of the reference adalimumab, Humira, used a citrate buffer to maintain the product within a predefined pH range. Similar systems are also used in products like etanercept and dulaglutide. In pivotal trials, this formulation of the reference Humira was linked with ISRs in 12.9% of patients.
Later, AbbVie, maker of the reference drug, reformulated its product to remove the citrate buffer in an effort to reduce both the product’s injection volume and the incidence of ISRs.
According to the NHS report, there is some weak evidence, derived from 2 small phase 2 studies, to support claims that citrate-free adalimumab, delivered via a 29-gauge needle, may provide some advantage over the original formulation, delivered by 27-gauge needle, in terms of reduced post-injection pain. However, the report’s authors point out, there is no consistent evidence that shows that the difference in discomfort between the 2 options persists longer than 15 minutes.
The report also details the excipients used in the biosimilar adalimumab products available in the NHS system, as well as data on ISRs:
Notably, among the adalimumab products available in syringe presentations, neither the reference nor any of the biosimilars’ devices contain latex. However, among adalimumab products available as prefilled pens, both Amgevita and Hyrimoz have needle covers that contain a derivative of latex, which could make them unsuitable for patients with latex allergies.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.